Compare · BTI vs KRBP
BTI vs KRBP
Side-by-side comparison of British American Tobacco Industries p.l.c. (BTI) and Kiromic BioPharma Inc. (KRBP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BTI and KRBP operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- BTI is the larger of the two at $130.80B, about 8644.0x KRBP ($15.1M).
- BTI has hit the wire 9 times in the past 4 weeks while KRBP has been quiet.
- BTI has more recent analyst coverage (14 ratings vs 0 for KRBP).
- Company
- British American Tobacco Industries p.l.c.
- Kiromic BioPharma Inc.
- Price
- $61.13+1.98%
- $1.48-1.33%
- Market cap
- $130.80B
- $15.1M
- 1M return
- +1.16%
- -
- 1Y return
- +28.71%
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NYSE
- NASDAQ
- IPO
- 1998
- 2020
- News (4w)
- 9
- 0
- Recent ratings
- 14
- 0
British American Tobacco Industries p.l.c.
British American Tobacco p.l.c. provides tobacco and nicotine products to consumers worldwide. It offers vapour products, tobacco heating products, and modern oral products; combustible products; and traditional oral products, such as Swedish-style snus and American moist snuff. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.
Kiromic BioPharma Inc.
Kiromic BioPharma, Inc., a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1; and chimeric gamma delta PD1 T cell switch receptor therapy. It has license agreements with Mercer University; CGA 369 Intellectual Holdings, Inc.; and Longwood University, as well as research and development collaboration agreements with Molipharma, S.R.L. and Leon Office (H.K.). The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.
Latest BTI
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- Large owner Bt De Investments Inc. converted options into 95,281,277 shares and was granted 14,662,765 shares (SEC Form 4)
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
Latest KRBP
- Kiromic BioPharma Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
- Kiromic BioPharma Inc. filed SEC Form 8-K: Other Events
- Amendment: SEC Form S-1/A filed by Kiromic BioPharma Inc.
- Kiromic BioPharma Reports Patient 4 in Deltacel-01 Clinical Trial Reaches 10-Month Progression-Free Survival
- SEC Form 10-K filed by Kiromic BioPharma Inc.
- Amendment: Kiromic BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Kiromic BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Kiromic BioPharma Reports Tumor Volume Decrease in Two Patients Enrolled in Deltacel-01
- SEC Form S-1 filed by Kiromic BioPharma Inc.
- Kiromic BioPharma Reports 32% Decrease in Tumor Volume Eight Months Post-Treatment in Fourth Patient Enrolled in Deltacel-01